SU938157A1 - Method of determination of human being microcirculator system state - Google Patents
Method of determination of human being microcirculator system state Download PDFInfo
- Publication number
- SU938157A1 SU938157A1 SU802961411A SU2961411A SU938157A1 SU 938157 A1 SU938157 A1 SU 938157A1 SU 802961411 A SU802961411 A SU 802961411A SU 2961411 A SU2961411 A SU 2961411A SU 938157 A1 SU938157 A1 SU 938157A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- blood
- esr
- microvasculature
- aggregation
- erythrocyte
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 15
- 210000003743 erythrocyte Anatomy 0.000 claims description 19
- 230000002776 aggregation Effects 0.000 claims description 15
- 238000004220 aggregation Methods 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000009534 blood test Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 230000004931 aggregating effect Effects 0.000 claims description 2
- 238000004159 blood analysis Methods 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 102000002262 Thromboplastin Human genes 0.000 claims 1
- 108010000499 Thromboplastin Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000005180 public health Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Изобретение относится к медицине в частности к метотрансфузиологии, и может быть использовано для контроля гемотрансфузионной терапии в хирургии, травматологии, реаниматологии, в клинике внутренних болезней 5 для дифференцированной терапии ряда заболеваний, протекающих с нарушенияг ми в микроциркуляторном русле.The invention relates to medicine, in particular to metotransfusiology, and can be used to control blood transfusion therapy in surgery, traumatology, resuscitation, in the clinic of internal diseases 5 for differentiated therapy of a number of diseases that occur with disorders in the microvasculature.
Известен способ определения состояния микроциркуляторного русла путем клинического анализа крови, опре деляющего способность эритроцитов агрегировать в ответ на добавление агрегирующего агента [1 ]. t5 A known method for determining the state of the microvasculature through a clinical blood test determines the ability of red blood cells to aggregate in response to the addition of an aggregating agent [1]. t5
Однако известный способ не обеспечивает достаточной точности.However, the known method does not provide sufficient accuracy.
Цель изобретения -повышение точности; способа определения состояния микроциркуляторного русла путем 20 клинического анализа крови.The purpose of the invention is improving accuracy; a method for determining the state of the microvasculature through 20 clinical blood tests.
Указанная цель достигается тем, что согласно способу определения состояния микроциркуляторного рус2 ла человека путем клинического анализа крови, кровь больного в двух равных объемах смешивают с равными объемами изотоничных по pH растворов, один из которых содержит стабилизатор и фосфатный буфер, а другой - стабилизатор, фосфатный буфер и формалин, далее ставят реакцию для определения скорости оседания эритроцитов (СОЭ) в обеих пробах и по коэффициенту агрегации эритроцитовопределяют состояние микроциркуляторного русла.This goal is achieved by the fact that according to the method for determining the state of the microvasculature of a person by clinical blood analysis, the patient’s blood in two equal volumes is mixed with equal volumes of pH isotonic solutions, one of which contains a stabilizer and a phosphate buffer, and the other a stabilizer, phosphate buffer and formalin, then set the reaction to determine the erythrocyte sedimentation rate (ESR) in both samples and determine the state of the microvasculature by the aggregation coefficient of erythrocytes.
Способ осуществляют следующим образом.The method is as follows.
По 0,5 мл крови исследуемого, взятой из локтевой вены, разливают в две силиконированные центрифужные пробирки, которые содержат по 2,0 мл раствора 1 и раствора 2 соответственно,после чего кровь перемешивают с растворами неоднократным покачиванием пробирок и из обеих проб ставят реакцию для определения СОЭ при по3 938157 4 мощи капилляров и аппарата Панченко в термостате при 37°С. Состав раствора 1:3,0 мл 0,077 М двузамещенного ЭДТА и 17,0 мл 0,1 Мфосфатного буфера pH 7,4, Состав раствора 2:3,0 мл 5 0,077 И двузамещенного ЭДТА, 5,0 мл 42-ного осветленного формалина и 12,0 мл 0,1 М фосфатного буфера pH 7,4, Оба раствора должны быть изот тоничны по pH 7,4. Коэффициент агре-. to гацйи вычисляют путем отношения СОЭ из пробы 1 к величине СОЭ из пробы 2. При отсутствии эритроцитарных агрегатов в крови коэффициент агрегации равен 1,0 и уменьшается по мере их 15 увеличения. ' ' Пример . Больной Н. Диагноз: инсулинозависимый сахарный диабет в стадии компенсации. При обследовании СОЭ Г = 12 мм/ч, а СОЭ 2 = 20 мм/ч. 20 Коэффициент агрегации 12 мм/ч :0.5 ml of the blood of the test, taken from the cubital vein, is poured into two siliconized centrifuge tubes, which contain 2.0 ml of solution 1 and solution 2, respectively, after which the blood is mixed with solutions by repeatedly shaking the tubes and from both samples the reaction for determination of ESR at 3,938,157 4 powers of capillaries and Panchenko apparatus in a thermostat at 37 ° С. The composition of the solution 1: 3.0 ml of 0.077 M disubstituted EDTA and 17.0 ml of 0.1 Mphosphate buffer pH 7.4, The composition of the solution 2: 3.0 ml of 5 0.077 And disubstituted EDTA, 5.0 ml of 42th clarified formalin and 12.0 ml of 0.1 M phosphate buffer pH 7.4. Both solutions should be isotonic with pH 7.4. Aggregate coefficient. to gatsiyi is calculated by the ratio of ESR from sample 1 to the value of ESR from sample 2. In the absence of red blood cells in the blood, the aggregation coefficient is 1.0 and decreases as they increase 15. '' Example. Patient N. Diagnosis: insulin-dependent diabetes mellitus in the stage of compensation. When examining ESR G = 12 mm / h, and ESR 2 = 20 mm / h. 20 Aggregation coefficient 12 mm / h:
i : 20 мм/ч = 0,6. Уменьшение коэффициента агрегации свидетельствует о нарушении состояния микроциркуляторного русла. После проведения кур- 25 са терапии препаратом Трентал, который как известно, уменьшает способность эритроцитов агрегировать, исследование проводят повторно. Получены следующие данные: СОЭ = 9 мм/ 30 /ч, а СОЭ 2=11 мм/ч. Коэффициент агрегации = 9:11 = 0,82, что. свидетельствует об улучшении состояния микроциркуляторного русла под влияние ем терапии препаратом Трентал.i: 20 mm / h = 0.6. A decrease in the aggregation coefficient indicates a violation of the state of the microvasculature. After the kur- 25 sa drug Trental therapy which is known to reduce the ability of red blood cells to aggregate, the research carried out repeatedly. The following data were obtained: ESR = 9 mm / 30 / h, and ESR 2 = 11 mm / h. Aggregation coefficient = 9:11 = 0.82, that. indicates an improvement in the state of the microvasculature under the influence of Trental therapy.
Применение предлагаемого способа 35 позволяет более точно оценить наличие эритроцитарных агрегатов в крови по “коэффициенту агрегации за счет того, что фиксированные форма лином эритроцитарные агрегаты имеют большой вес пр сравнению с отдельными эритроцитами, что и обуславливает изменение СОЭ в пробе 2, использовать небольшое количество крови (1,0 мл вместо 5,0 мл согласно известному^ а также назначать адекватную терапию при ряде заболеваний, протекающих с нарушениями в микроциркуляторном русле. Простота осуществления способа делает его доступным широкому кругу медицинских учреждений практического здравоохранения.The application of the proposed method 35 allows a more accurate assessment of the presence of erythrocyte aggregates in the blood by the “aggregation coefficient due to the fact that the fixed-form erythrocyte aggregates have a large weight compared to individual red blood cells, which leads to a change in ESR in sample 2, to use a small amount of blood ( 1.0 ml instead of 5.0 ml according to the known ^ and also prescribe adequate therapy for a number of diseases that occur with disorders in the microvasculature. The simplicity of the method makes it accessible to a wide range of medical institutions of practical health care.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU802961411A SU938157A1 (en) | 1980-07-25 | 1980-07-25 | Method of determination of human being microcirculator system state |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU802961411A SU938157A1 (en) | 1980-07-25 | 1980-07-25 | Method of determination of human being microcirculator system state |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU938157A1 true SU938157A1 (en) | 1982-06-23 |
Family
ID=20910171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU802961411A SU938157A1 (en) | 1980-07-25 | 1980-07-25 | Method of determination of human being microcirculator system state |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU938157A1 (en) |
-
1980
- 1980-07-25 SU SU802961411A patent/SU938157A1/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cohen et al. | Pica and elevated blood lead level in autistic and atypical children | |
| Boyle et al. | Serum uric acid levels in normal pregnancy with observations on the renal excretion of urate in pregnancy | |
| Petty et al. | Clinical correlates of antinuclear antibodies in juvenile rheumatoid arthritis | |
| SU1767433A1 (en) | Method of determining insulin resistance of immunogenesis in patients with type 1 diabetes mellitus | |
| WO1984002982A1 (en) | Serum fibrinogen viscosity in clinical medicine | |
| Chen et al. | Comparative studies of asymptomatic proteinuria and hematuria | |
| SU938157A1 (en) | Method of determination of human being microcirculator system state | |
| RU2275640C1 (en) | Method for selecting thrombocytopathy treatment approach in metabolic syndrome cases | |
| Laiwah et al. | Australia antigen in west of Scotland and north of England | |
| Plass et al. | A new procedure for determining blood sedimentation rates | |
| Lubschez | Studies in ascorbic acid with especial reference to the white layer. I. Description of method and comparison of ascorbic acid levels in whole blood, plasma, red cells, and white layer | |
| Schroeder et al. | Detection of hemoglobins S and C at birth: A rapid screening procedure by column chromatography | |
| RU2063041C1 (en) | Method of estimation of organism resistance decrease to infection in leukosis patients | |
| RU2286580C1 (en) | Method for diagnosing beginning blood platelets aggregation disorders | |
| RU2073869C1 (en) | Method to evaluate stenocardia degree | |
| SU1348732A1 (en) | Method of determining short-term pregnancy | |
| RU2098823C1 (en) | Method for predicting hypoxic therapy effectiveness in patients suffering from bronchial obstruction syndrome | |
| SU1631432A1 (en) | Method for differential diagnosis of child circumscribed and systemic scleroderma | |
| SU1491520A1 (en) | Method of determining personal sensitivity to hemosorption in diabetes melitis | |
| SU1446572A1 (en) | Method of differential diagnosis of insulin-independent and insulin-dependent diabetes mellitus | |
| RU2176508C2 (en) | Agent for evaluation of endotoxemia manifestation and degree of disease severity | |
| McIntyre et al. | Lag times between blood sampling, spinning and plasma glucose estimation | |
| RU2275641C1 (en) | Early stage diagnosis method for detecting thrombophilic thrombocytopathy in metabolic syndrome cases | |
| SU1561038A1 (en) | Method of diagnosis of rheumatic myocarditis | |
| RU1808334C (en) | Agent increasing erythrocyte deformability |